Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function

D Ontaneda, AJ Thompson, RJ Fox, JA Cohen - The Lancet, 2017 - thelancet.com
Multiple sclerosis is a major cause of neurological disability, which accrues predominantly
during progressive forms of the disease. Although development of multifocal inflammatory …

Cognitive impairment in multiple sclerosis

ND Chiaravalloti, J DeLuca - The Lancet Neurology, 2008 - thelancet.com
Multiple sclerosis (MS) is a progressive disease of the CNS that is characterised by
widespread lesions in the brain and spinal cord. MS results in motor, cognitive, and …

Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings

AJ Coles, JA Cohen, EJ Fox, G Giovannoni… - Neurology, 2017 - AAN Enterprises
Objective: To evaluate 5-year efficacy and safety of alemtuzumab in patients with active
relapsing-remitting multiple sclerosis and inadequate response to prior therapy. Methods: In …

Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study

AJC Eijlers, Q van Geest, I Dekker, MD Steenwijk… - Brain, 2018 - academic.oup.com
Cognitive decline is common in multiple sclerosis and strongly affects overall quality of life.
Despite the identification of cross-sectional MRI correlates of cognitive impairment …

Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis

M Calabrese, F Agosta, F Rinaldi, I Mattisi… - Archives of …, 2009 - jamanetwork.com
Background Neuropsychological deficits in patients with multiple sclerosis (MS) have been
shown to be associated with the major pathological substrates of the disease, ie …

The clinico-radiological paradox in multiple sclerosis revisited

F Barkhof - Current opinion in neurology, 2002 - journals.lww.com
The use of magnetic resonance imaging as a surrogate outcome measure in clinical trials, or
even as a prognosticator in the assessment of the natural evolution, assumes a close …

Brain atrophy and lesion load predict long term disability in multiple sclerosis

V Popescu, F Agosta, HE Hulst, IC Sluimer… - Journal of Neurology …, 2013 - jnnp.bmj.com
Objective To determine whether brain atrophy and lesion volumes predict subsequent 10
year clinical evolution in multiple sclerosis (MS). Design From eight MAGNIMS (MAGNetic …

Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options

A Andravizou, E Dardiotis, A Artemiadis… - Autoimmunity …, 2019 - Springer
Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system
characterized by focal or diffuse inflammation, demyelination, axonal loss and …

Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis

D Miller, F Barkhof, X Montalban, A Thompson… - The Lancet …, 2005 - thelancet.com
In 85% of young adults with multiple sclerosis (MS), onset is a subacute clinically isolated
syndrome (CIS) of the optic nerves, brainstem, or spinal cord. Methods of assessing the …

The mechanism of action of interferon-β in relapsing multiple sclerosis

BC Kieseier - CNS drugs, 2011 - Springer
Multiple sclerosis (MS) is characterized by autoimmune inflammation and subsequent
neurodegeneration. It is believed that early in the disease course, proinflammatory T cells …